Institutional Ownership
Newamsterdam Pharma Company
CUSIP N62509117*W EXP 99/99/999Q1 2026
13D / 13G Filings
0
Schedule 13D/13G on record
Beneficial Filers
0
Distinct reporting persons
Largest Stake
—
Max % of class reported
Institutional Holders
9
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
Schedule 13D (activist) & 13G (passive) 5%+ ownership filings
No 13D/13G filings on record yet
Schedule 13D/13G beneficial-ownership filings from 2020–present are ingested from SEC EDGAR. Coverage expands as the backfill and daily crawler run.
Top Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 500.3K | $10.03M |
| 2 | Ra Capital Management, L.P. | 333.3K | $6.68M |
| 3 | Affinity Asset Advisors, LLC | 245.0K | $4.91M |
| 4 | Bain Capital Life Sciences Investors, LLC | 100.0K | $2.00M |
| 5 | Deerfield Management Company, L.P. | 92.8K | $1.86M |
| 6 | Aristeia Capital, L.L.C. | 15.7K | $342.7K |
| 7 | Wolverine Asset Management LLC | 2.1K | $42.6K |
| 8 | Ubs Group AG | 396 | $7.9K |
| 9 | Vestcor Inc | 6.7K | $131 |